A FGFR4‐targeted drug, BLU‐554, has been evaluated in a Phase 1 clinical trial by Blueprint Medicines and the result showed great potential for controlling HCC progression (https://clinicaltrials.gov/ct2/show/NCT02508467). The gene discussed is FGFR4; the disease is hepatocellular carcinoma.